The company announced strengthening its leadership/team by adding a highly experienced US-based public markets executive. The update is tied to continued late-stage development progress for LEVI-04 targeting osteoarthritis, but no efficacy, regulatory, or financial milestones were provided.
The company announced strengthening its leadership/team by adding a highly experienced US-based public markets executive. The update is tied to continued late-stage development progress for LEVI-04 targeting osteoarthritis, but no efficacy, regulatory, or financial milestones were provided.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
neutral
Sentiment Score
0.10
